CUMULATIVE INDEX 2000 Volume 18 January NEW AND EMERGING THERAPIES, pages 1-200 April DELIVERY OF DERMATOLOGIC HEALTH CARE, pages 201-382 July INPATIENT DERMATOLOGY, pages 383-556 November DERMATOLOGIC ASPECTS OF COSMETICS, pages 557-741 Note: Page numbers of article titles are in boldface type. Accutane, for cutaneous T-cell lymphomas, 152 8-Amino-levulinic acid, for cutaneous T-cell Acitretin, for psoriasis, 16 lymphomas, 151 Acne, cosmetics and, 696 Amlexanox, for aphthous stomatitis, 116 sebaceous glands and, 617-619 Amniotic membranes, as skin grafts, 522 treatment of, 63-68 Amphotericin B, for infectious diseases, 32 hormonal therapy in, 67-68 Anaphylaxis, pulse intravenous cyclophosphamide and, isotretinoin in, 63-65 464 and depression, 65 Androgen metabolism, in pilosebaceous unit, 69-70 in elderly, 64 Androgenetic alopecia, biochemical mechanisms of, intermittent dosing of, 64 47-48 patterns of use of, 63-64 treatment of, 47-61 skeletal effects of, 65 Aminexil in, 56 minocycline in, 65-66 amino acids in, 55 potential future therapies in, 69-70, 704-705 antisense technology in, 59 topical retinoids in, 66-67 Arnica in, 57 unusual remedies for, 327 biotin in, 55 Acrodermatitis, Hallopeau's, treatment of, 341 Black Bryony in, 57 Acrodermatitis continua, clinical features of, 428 cimetidine in, 52 Actinic keratoses, unusual remedies for, 324 cyproterone acetate in, 51-52 Acyclovir, for infectious diseases, 31 ElectroTrichoGenesis in, 60 Adapalene, for acne, 66-67 Fabao lOlD in, 54 Akithisia, antipsychotic agents and, 721 finasteride in, 48-49 Aliretinoid, for Kaposi's sarcoma, 172-173 FK-143 in, 58 Alkyl ether sulfates, in skin cleansers, 566 flutamide in, 51 Alkyl glyceryl ether sulfonates, in skin cleansers, 566 folic acid in, 55 Alkyl sulfates, in skin cleansers, 566 folligen in, 55 Allergic reactions, to lip cosmetics, 646-647 Formula 101 in, 54 AlloDerm, as skin substitute, 528 gene therapy in, 59 Allopurinol, and toxic epidermal necrolysis, 488 G1198745 in, 58 Alopecia, androgenetic. See Androgenefic alopecia. horsetail in, 57 pulse glucocorticoids for, 441 lamin in, 54 pulse intravenous cyclophosphamide and, 463 in women, 58-59 unusual remedies for, 327-328 Kevis Hair Rejuvenation Program in, 53-54 Alpha hydroxy acids, in cosmetics, mechanism of action laser light therapy in, 60 of, 613 maidenhair in, 57 in moisturizers, 601-602 minoxidil in, 49 topical, for photoaging, 103-105 Nioxin system in, 55-56 Alternative medicine. Complementary and alternative Permixon in, 52-53 medicine. Piliel in, 56 Amenorrhea, pulse intravenous cyclophosphamide and, polysorbate 80 in, 54-55 465 progesterone in, 51 Americans with Disabilities Act, and dermatologic saw palmetto in, 53 health care, 315 Serenoa repens in, 52 Aminexil, for androgenetic alopecia, 56 Smart Hair Care Program in, 55 Amino acids, for androgenetic alopecia, 55 spironolactone in, 49-51 727 728 CUMULATIVE INDEX 2000 Androgenetic alopecia (Continued) Azathioprine, clinical uses of, 476-477 ThymuSkin in, 56-57 for atopic dermatitis, 6 Tricologic Biowave Helmet in, 60 for bullous pemphigoid, 128 turosteride in, 58 for cutaneous lupus erythematosus, 140 ViviScal in, 56 for cutaneous vasculitis, 144 zinc in, 54 for erythema multiforme, 117 Angiosarcoma, clinical features of, 546-547 Azelaic acid, for melasma, 94 Angiostatin, for Kaposi's sarcoma, 172 Azithromycin, for bacterial skin infections, in children, Anthracyclines, for Kaposi's sarcoma, 170-171 75-76 Anthralin, for psoriasis, 39, 430-431 Antiangiogenic factors, for Kaposi's sarcoma, 171-172 Antianxiety agents, in dermatology, 714, 717 Antibacterial agents, in skin cleansers, 570 Baby shampoos, in hair care, 656 Antibiotics, for atopic dermatitis, 3 Bacille Calmette-Guerin, for infectious diseases, 34 for infectious diseases, 32-33 for melanoma, 163 Anticonvulsants, and toxic epidermal necrolysis, 487 Bacterial skin infections, treatment of, in children, 75-76 Antidepressant agents, in dermatology, 717-719 Bactrim, for HIV infection, adverse effects of, 513 Antifungal agents, for infectious diseases, 32 Balsam of Peru, in cosmetics, adverse reactions to, 686 Antihistamines, for atopic dermatitis, 8 Behget's disease, treatment of, 115-116 Anti-inflammatory agents, for atopic dermatitis, 7-8 Benchmarking, in inpatient dermatology, 403 Antilepromatous agents, for cutaneous lupus Benzalkonium chloride, in cosmetics, adverse reactions erythematosus, 140 to, 690 Antimalarial agents, for cutaneous vasculitis, 143 Benzodiazepines, in dermatology, 714, 717 Antioxidants, cosmetic uses of, in future, 703-704 Benzophenones, in sunscreens, 582 in cosmetics, mechanism of action of, 611-613 Beta hydroxy acid, in moisturizers, 602-603 in lip cosmetics, 647 Betaines, in skin cleansers, 566-567 in photoprotection, 585-586 Betamethasone valerate mousse, for psoriasis, 13 Antipsychotic agents, in dermatology, 719-721 B-F5, for atopic dermatitis, 9 Antisense technology, for androgenetic alopecia, 59 Biobrane, for toxic epidermal necrolysis, 24 Antiviral agents, for infectious diseases, 31-32 Biochemotherapy, for melanoma, 161-162 Aphthous stomatitis, treatment of, 115-116 Biological response modifiers, for cutaneous T-cell unusual remedies for, 328 lymphomas, 151-153, 420 Apligraf, as skin substitute, 529 Biopsies, of skin cancer, 254-255 Arnica, for androgenetic alopecia, 57 sentinel lymph node, for melanoma, 158-159 Aromachology, cosmetic uses of, in future, 709 Biotin, for androgenetic alopecia, 55 Artificial nail sculptures, dermatologic aspects of, Black Bryony, for androgenetic alopecia, 57 680-683 Black eye, unusual remedies for, 323-324 Artificial nail tips, dermatologic aspects of, 678, 680 Black hairy tongue, unusual remedies for, 328 Atopic dermatitis, treatment of, 1-11 Bleeding, unusual remedies for, 324 antihistamines in, 8 Blepharitis, seborrheic, unusual remedies for, 329 azathioprine in, 6 Blistering diseases, treatment of, 127-137 B-F5 in, 9 autoimmune diseases, intravenous immunoglobulin cyclosporine in, 3-4 in, 453-454 evening primrose oil in, 8 pulse glucocorticoids in, 441 interferons in, 6 bullous pemphigoid, 127-129 intravenous immunoglobulin in, 6-7, 454-455 azathioprine in, 128 leukotriene inhibitors in, 8 methotrexate in, 128-129 maintenance alternatives in, 3 mycophenolate mofetil in, 129 methotrexate in, 4, 6 of oral cavity, 117 mycophenolate mofetil in, 7 pulse intravenous cyclophosphamide in, 468 phosphodiesterase inhibitors in, 7-8 steroids in, 128 SDZ ASM 981 in, 4 cicatricial pemphigoid, 129-131 skin care versus allergy care in, 1 prednisone in, 130 skin hydration in, 2 epidermolysis bullosa acquisita, 131-132 sodium cromoglycate in, 9 linear immunoglobulin A bullous dermatosis, 132 steroids in, adequate versus risky, 2 paraneoplastic pemphigus, 134-135 tacrolimus in, 4 pemphigus, 132-134 thalidomide in, 8 dapsone in, 133 traditional Chinese medicine in, 8-9 mycophenolate mofetil in, 133 UV light in, 7 steroids in, 133 Atypical fibroxanthoma, clinical features of, 544-545 Blood pressure, increases in, cyclosporine and, 478 Auranofin, for cutaneous lupus erythematosus, 140-141 Blushes, facial, 627 Autografts. See Skin grafts. Body piercing, in adolescents, 671-672 Autoimmune bullous diseases, intravenous Bone marrow toxicity, of chlorambucil, 481 immunoglobulin for, 453-454 of thioguanine, 480 pulse glucocorticoids for, 441 Bone marrow transplantation, for cutaneous T-cell Autoimmune dermatoses, intravenous immunoglobulin lymphomas, 154 for. See Intravenous immunoglobulin. Bone mineral density, pulse glucocorticoids and, 442 Autologous grafts, for vitiligo, 81-82 Brain metastases, from melanoma, radiation therapy for, Avobenzone, in sunscreens, 583 164 CUMULATIVE INDEX 2000 729 Brittle nails, treatment of, 344 localized scleroderma, 142-143 Bullous diseases, treatment of. See Blistering diseases. Colophony, in cosmetics, adverse reactions to, 690 Burdeo lotion, unusual uses for, 336 Colored facial cosmetics, 621-631 Butenafine, for onychomycosis, in children, 44 blushes, 627 Butyl methoxydibenzoylmethane, in sunscreens, 583 for camouflaging, 627-630 application of, 629-630 choice of, 629 color abnormality, 629 Calcinosis, cutaneous dermatomyositis and, 142 contour abnormalities, 628-629 Calcipotriene, for psoriasis, 13-14, 38-39 manufacturers of, 631 Calcitriol, for localized scleroderma, 142 foundation, 621-625 for psoriasis, 18 application of, 623 Camouflage cosmetics. See Colored facial cosmetics. availability of, 623-624 CAMPATH-1 monoclonal antibodies, for graft-versus- cost of, 624 host disease, 25 dermatologic uses of, 625 Camphor derivatives, in sunscreens, 582 formulation of, 622 Cancer, of lip, prevention of, lip cosmetics in, 648 photoprotection in, 624 Candidiasis, unusual remedies for, 329 surface characteristics of, 622-623 Carcinogenic effects, of pulse intravenous therapeutic, 624-625 cyclophosphamide, 462-463 types of, 625 Cardiac toxicity, of pulse intravenous historical aspects of, 558 cyclophosphamide, 463 powders, 625-627 Cardiovascular complications, of pulse glucocorticoids, application of, 626 442 dermatologic uses of, 626-627 Cellulitis, inpatient treatment of, 497-498 formulation of, 626 Cheilitis, lip cosmetics and, 646 specialty products related to, 626 unusual remedies for, 329 Comedogenesis, cytokines in, 69 Chemical peels, for melasma, 94 Complementary and alternative medicine, 189-193 for photoaging, 107 American Medical Association and, 190 for postinflammatory hyperpigmentation, 96-97 definitions of, 190 Chemotherapy, for cutaneous T-cell lymphomas, demographics of, 190-191 153-154, 420 in dermatology, 193 for Kaposi's sarcoma, 169-171 lack of scientific evidence in, 192 for melanoma, 161 politics and regulations in, 191 Chinese medicine, for atopic dermatitis, 8-9 products used in, 191-192 Chlorambucil, clinical uses of, 480-481 risks of, 192-193 Chlorhexidine, in cosmetics, adverse reactions to, 690 Conditioners, in hair care, 656-657 Chloroquine, for cutaneous lupus erythematosus, 139 Condylomata acuminata, unusual remedies for, 327 Cicatricial pemphigoid, of oral cavity, treatment of, Contact dermatitis, cosmetics and, 685-686 117-118 in adolescents, 672 treatment of, 129-131 lip cosmetics and, 646 pulse intravenous cyclophosphamide in, 468-469 unusual remedies for, 328-329 Cidofovir, for verrucae vulgaris, in children, 76 Contact urticaria, cosmetics and, 694-695 Cimetidine, for androgenetic alopecia, 52 Contraceptives, oral, for acne, 67-68 Cinnamates, in sunscreens, 582 Copper, in cosmetics, mechanism of action of, 611 Cleansers, in hair care, 655-656 Copper chloride, for androgenetic alopecia, 55 skin. See Skin cleansers. CosmeceuHcals, 288, 609-615 Clinical Laboratory Improvement Amendments, and clinical trials in, 613 dermatologic health care, 313-314 future of, 699-701 Clofazimine, for cutaneous lupus erythematosus, 140 mechanism of action of active ingredient in, 611-613 for erythema dyschromicum perstans, 96 nomenclature in, 609-610 Coblation, for photoaging, 108 penetration and delivery of active ingredient in, 610 Cochrane Library, in evidence-based dermatologic Cosmetics, dermatologic aspects of, 28^289 health care, 263 adverse reactions, 685-698 Cocoyl isethionates, in skin cleansers, 565-566 acne cosmetica, 696 Colchicine, for cutaneous vasculitis, 143-144 contact dermatitis, 646, 672, 685-686 Collagen-vascular diseases, treatment of, 139-146 contact urticaria, 694-695 cutaneous dermatomyositis, 141-142 photoallergy, 694 cutaneous lupus erythematosus, 139-141 sensitive skin in patch test-negative patient, auranofin in, 140-141 695-696 azathioprine in, 140 to benzalkonium chloride, 690 chloroquine in, 139 to chlorhexidine, 690 clofazimine in, 140 to colophony, 690 cytokines in, 141 to detergents and foam boosters, 690 dapsone in, 140 to emulsifiers, 693 intravenous immunoglobulin in, 140 to Euxyl K400, 689 phenytoin in, 141 to flavoring ingredients, 687 retinoids in, 141 to formaldehyde-releasing preservatives, 688-689 thalidomide in, 140 to fragrance, 686-687 cutaneous vasculitis, 143-144 to hair care products, 690-692 730 CUMULATIVE INDEX 2000 Cosmetics (Continued) Cutaneous lupus erythematosus, unusual remedies for, to iodopropynyl butylcarbamate, 689-690 332 to Kathon CG, 689 Cutaneous T-cell lymphomas, clinical features of, to lanolin, 692 417-418 to nail cosmetics, 692 inpatient treatment of, 422^23 to parabens, 689 photopheresis in, 418-420 to propylene glycol, 692 pathogenesis of, 147-148, 418 to sorbic acid, 690 treatment of, 147-156 to sunscreens, 693 8-amino-levulinic acid in, 151 to thimerosol, 690 bone marrow transplantation in, 154 colored facial cosmetics. See Colored facial cosmetics. chemotherapy in, 153-154 cosmeceuticals. See Cosmeceuticals. cytokines in, 152 eye cosmetics. See Eye cosmetics. hypericin in, 151 hair care. See Hair care. interferons in, 151-154 historical aspects of, 557-559 interleukins in, 149-152 colored facial cosmetics, 558 photodynamic therapy in, 151 eye cosmetics, 558 phototherapy in, 149 lip cosmetics, 558-559, 641 retinoids in, 152-153 nail cosmetics, 559 targretin in, 151 soap and cleansing, 557-558, 561-562 Cutaneous tumors, unusual, 543-552 in adolescents, 667-673 angiosarcoma, 546-547 cleansers, 668 atypical fibroxanthoma, 544-545 contact dermatitis, 672 dermatofibrosarcoma protuberans, 543-544 demographics and trends in, 667-668 extramammary Paget's disease, 547-548 hair coloring, 669-670 leiomyosarcoma, 549-550 hair removal, 670 malignant fibrous histiocytoma, 545-546 hair-setting agents, 669 Merkel's cell carcinoma, 548-549 moisturizers, 669 sebaceous carcinoma, 550-551 of color, 670 Cyclophosphamide, for paraneoplastic pemphigus, 135 permanent waves, 670 for pemphigoid, of oral cavity, 117-118 photoprotection, 668-669 for pemphigus, of oral cavity, 120 pomades, 670 pulse intravenous. See Pulse intravenous cyclophospha¬ product claims, 670-671 mide. tattooing and body piercing, 671-672 Cyclosporine, clinical uses of, 477-478 in future, 699-709 for atopic dermatitis, 3-4 claim substantiation, 707 for epidermolysis bullosa acquisita, 131 cosmeceuticals, 699-701 for lichen planus, 21-22 herbs, 701-702 for psoriasis, 16-17, 356 heuristics versus hedonics, 708-709 for vitiligo, 87 miscellaneous ingredients, 705-706 Cyproterone acetate, for androgenetic alopecia, 51-52 negative advertising, 706-707 Cystitis, hemorrhagic, pulse intravenous perfect sunscreen, 708 cyclophosphamide and, 462 therapeutic cosmetology, 704-705 Cysts, unusual remedies for, 324 topical vitamins, 702-704 Cytochrome P-450 isoenzymes, in drug-drug uses for petrolatum, 707-708 interactions, 721-722 uses for tars, 708 Cytokine antagonists, for graft-versus-host disease, in women of color. See Women of color. 25-26 lip cosmetics. See Lip cosmetics. Cytokines, for cutaneous lupus erythematosus, 141 moisturizers. See Moisturizers. for cutaneous T-cell lymphomas, 152 nail cosmetics. See Nail cosmetics. for vitiligo, 85-88 photoprotection. See Photoprotection. in comedogenesis, 69 sebaceous glands. See Sebaceous glands. Cytotoxic agents, for cutaneous lupus erythematosus, skin cleansers. See Skin cleansers. 140 tanning agents. See Tanning agents. for Kaposi's sarcoma, 169-171 Crude coal tar, for psoriasis, 429 Crural intertrigo, unusual remedies for, 331-332 Cultured allografts, as skin grafts, 527-528 Cultured autografts, as skin grafts, 527 Dacarbazine, for melanoma, 161, 162 Cutaneous collagen-vascular diseases, treatment of. See Dandruff shampoos, in hair care, 656 Collagen-vascular diseases. Dapsone, for aphthous stomatitis, 115 Cutaneous drug eruptions, with HIV infection, 511, 513 for cutaneous lupus erythematosus, 140 Cutaneous infections, inpatient treatment of, 497-508 for cutaneous vasculitis, 143 disseminated herpes zoster, 506-507 for pemphigus, 133 ehrlichiosis, 504 Daunorubicin, for Kaposi's sarcoma, 170-171 erysipelas and cellulitis, 497-498 Delavirdine, for HIV infection, adverse effects of, 513 meningococcemia, 504-506 Depression, isotretinoin and, 65 necrotizing fasciitis, 498-499 Dermabrasion, for melasma, 94 Rocky Mountain spotted fever, 503-504 for photoaging, 107 staphylococcal scalded skin syndrome, 499-501 Dermagraft-TC, as skin substitute, 528-529 toxic shock syndrome, 501-503 Dermal skin substitutes, as skin grafts, 528-529 CUMULATIVE INDEX 2000 731 Dermatitis, atopic. See Atopic dermatitis. primary care physician in. See Primary care physician. contact. See Contact dermatitis. state societies in, 319-322 Dermatofibrosarcoma protuberans, clinical features of, annual meetings of, 321 543-544 establishment of, 319-320 Dermatologic health care, economics of, 211-214 expanding benefits and services of, 320-321 in Canada, 212-213 unusual remedies in, 323-337 in France, 213-214 for acne, 327 in Germany, 212 for actinic keratoses, 324 in United Kingdom, 213 for alopecia, 327-328 evidence-based. See Evidence-based dermatologic health for aphthous stomatitis, 328 care. for atopic dermatitis, 328-329 for skin cancer. See Skin cancer. for black eye and periorbital hematoma, 323-324 impediments to, 313-317 for black hairy tongue, 328 Americans with Disabilities Act, 315 for bleeding, 324 Clinical Laboratory Improvement Amendments, for condylomata acuminata, 327 313- 314 for crural intertrigo, 331-332 direct access regulations, 316 for cutaneous lupus erythematosus, 332 Food and Drug Administration, 315 for cysts, 324 Health Care Financing Administration, 315-316 for disseminated superficial actinic porokeratosis, Occupational Safety and Health Administration, 324-325 314- 315 for dry skin, 329-330 outpatient surgery regulations, 316-317 for dyshidrosis, 330 in developing world, 201-210 for facial erythema, 330 academic curricula in, 203-204 for facial scarring, 324 allied health professionals in, 202-203 for factitial disease and localized neurodermatitis, clean water in, 209-210 330 definition of, 202 for flat warts, 326-327 dermatology nursing in, 208-209 for folliculitis and furunculosis, 327 essential drugs in, 209 for granuloma annulare, 330 for leprosy, 208 for habit tic nail deformity, 333 in China and India, 206-207 for Hailey-Hailey disease, 331 in Eastern Europe and former Russian Empire, 207 for herpes simplex, 331 in island communities, 206 for hidradenitis suppurativa, 331 in Latin America, 207 for hyperhidrosis, 3^ in West Africa, 206 for infected foot dermatoses, 331 International Foundation for Dermatology in, 204- for ingrown toenail, 324 205 for insect bites, 332 Regional Dermatology Training Centre in, 205-206 for keratoacanthoma, 325 threats to, 203 for leg ulcers, 335 World Health Organization in, 207-208 for molluscum contagiosum, 325 in minority populations. See Minority popndations. for moniliasis, 332 in twenty-first century, 241-249 for morphea, 332 dermatopathology in, 242-243 for onychomycosis, 332-333 improving cost-effectiveness of, 248 for painful fissures, 330 in managed care environment, 244-247 for paronychia, 332 in United States, 243-244 for perioral dermatitis, 329 overview of, 241-242 for polymorphous light eruption, 333 telemedicine in, 247-248 for pretibial myxedema, 333 manpower needs in, 303-312 for pruritus, 333-334 cosmetic versus medical dermatology in, 310-311 for pruritus ani, 333 declining interest in medical dermatology in, 307- for psoriasis, 334 308 for pyoderma gangrenosum, 334 declining treatment by dermatologists in, 306-307 for rosacea, 334-335 delivering and paying for care in, 304-305 for scaling scalp, 335 factual data on, 304 for sebaceous hyperplasia, 325 future provider supply in, 305 for seborrheic dermatitis, 329 maldistribution of, 305-306 for slow healing, 324 predicting future needs in, 309-311 for split nails, 332 quality of training in, 308-309 for stasis dermatitis, 335 National Ambulatory Medical Care Survey of. See Na¬ for sunburn, 331 tional Ambulatory Medical Care Survey. for tinea, 335 occupational. See Occupational dermatologic health care. for tuberous xanthoma, 325 patient advocacy groups in. See Patient advocacy for urticaria, 335 groups. for vitiligo, 336 pearls on medications, tools, and appliances, 336-337 for vulvodynia, 336 pharmaceutical industry in. See Pharmaceutical indus¬ for warts, 325-326 try. Dermatology, inpatient. See Inpatient dermatology. physician assistants in, 297-302 Dermatomyositis, treatment of, 141-142 functions of, 299-301 intravenous immunoglobulin in, 451-453 historical aspects of, 297-298 Dermatoses, infected foot, unusual remedies for, 331 732 CUMULATIVE INDEX 2000 Dermatoses (Continued) histopathology of, 408, 411 intravenous immunoglobulin for. See Intravenous im¬ inpatient treatment of, 412 munoglobulin. laboratory features of, 408 lichenoid. See Lichenoid dermatoses. natural course of, 412 Diaper dermatitis, unusual remedies for, 329 prognosis for, 412 Dihydroxyacetone. See Tanning agents. systemic complications of, 411-412 Disseminated herpes zoster, inpatient treatment of, 2-Ethylhexyl-2-cyano-3,3-diphenylacrylate, in 506-507 sunscreens, 582 Disseminated superficial actinic porokeratosis, unusual Etretinate, for cutaneous T-cell lymphomas, 152 remedies for, 324-325 for lichen planus, 22 Doxorubicin, for Kaposi's sarcoma, 170 for psoriasis, 15-16 Drug-induced hyperpigmentation, treatment of, 95 Euxyl K400, in cosmetics, adverse reactions to, 689 Dry skin, moisturizers for. See Moisturizers. Evening primrose oil, for atopic dermatitis, 8 unusual remedies for, 329-330 Evidence-based dermatologic health care, 261-276 Dyschromias, in women of color, cosmetics for, 661-663 advantages of, 271 Dyshidrosis, unusual remedies for, 330 application of evidence in, 269 appraisal of evidence in, 264-269, 274-276 results of, 265 terms and concepts in, 265-269 Eczema, of nails, treatment of, 344 case-control study, 267-269 Ehrlichiosis, inpatient treatment of, 504 cohort study, 267 Electron beam radiation therapy, for cutaneous T-cell confidence interval, 266-267 lymphomas, 154 likelihood ratio, 265 ElectroTrichoGenesis, for androgenetic alopecia, 60 odds ratio, 267-269 EMBASE, in evidence-based dermatologic health care, Cochrane Library in, 263 264 EMBASE in, 264 Emerging therapies, complementary and alternative example of, 269-270 medicine in. See Complementary and alternative finding best evidence in, 262-264 medicine. formulating clinical questions in, 262 for acne. See Acne. grades of evidence in, 273 for androgenetic alopecia. See Androgenetic alopecia. MEDLINE in, 263-264 for atopic dermatitis. See Atopic dermatitis. objections to, 270-271 for blistering diseases. See Blistering diseases. recording evidence in, 269 for collagen-vascular diseases. See Collagen-vascular Extramammary Paget's disease, clinical features of, diseases. 547-548 for cutaneous T-cell lymphomas. See Cutaneous T-cell Eye cosmetics, 633-639 lymphomas. artificial eyelashes, 638 for hyperpigmentation. See Hyperpigmentation. creams, 633 for infectious diseases. See Infectious diseases. eyebrow cosmetics, 638-639 for Kaposi's sarcoma. See Kaposi's sarcoma. eyelash dyes, 638 for lichenoid dermatoses. See Lichenoid dermatoses. eyeliner, 635-637 for melanoma. See Melanoma. tattooing of, 635-636 for oral cavity diseases. See Oral cavity diseases. historical aspects of, 558 for photoaging. See Photoaging. mascara, 637-638 for psoriasis, ^e Psoriasis. shadow, 633-635 for rosacea. See Rosacea. shadow base, 633 for vitiligo. See Vitiligo. gene therapy in. See Gene therapy. in pediatric dermatology. See Pediatric dermatology. Emulsifiers, in cosmetics, adverse reactions to, 693 Fabao lOlD, for androgenetic alopecia, 54 Endostatin, for Kaposi's sarcoma, 172 Facial cosmetics, colored. See Colored facial cosmetics. Enoxaparin, for lichen planus, 23 Facial erythema, unusual remedies for, 330 of oral cavity, 114 Facial scarring, unusual remedies for, 324 Ensilizole, in sunscreens, 582-583 Factitial disease, unusual remedies for, 330 Eosinophilic folliculitis, with HIV infection, Famciclovir, for infectious diseases, 31 phototherapy for, 517 Fibrosis, hepatic, methotrexate and, 476 Epidermal skin substitutes, as skin grafts, 527, 529 Fibrous histiocytoma, malignant, clinical features of, Epidermolysis bullosa acquisita, treatment of, 131-132 545-546 intravenous immunoglobulin in, 453^54 Fibroxanthoma, atypical, clinical features of, 544-545 Erysipelas, inpatient treatment of, 497-498 Finasteride, for androgenetic alopecia, 48-49 Erythema, facial, unusual remedies for, 330 Fissures, painful, unusual remedies for, 330 Erythema dyschromicum perstans, treatment of, 95-96 Fixed drug eruptions, treatment of, 95 Erythema multiforme, treatment of, 116-117 FK-143, for androgenetic alopecia, 58 versus toxic epidermal necrolysis, 485-486 FK-506, for atopic dermatitis, 4 Erythroderma, 405-415 for graft-versus-host disease, 26 clinical features of, 407 Flavoring ingredients, in cosmetics, adverse reactions to, diagnostic clues in, 407-408 687 diseases manifesting as, 405 Fluconazole, for onychomycosis, 42-43 drug-induced, 405-406 in children, 44 epidemiology of, 406 for tinea capitis, in children, 73-74 CUMULATIVE INDEX 2000 733 Fludarabine, for cutaneous T-cell lymphomas, 153-154 Hailey-Hailey disease, unusual remedies for, 331 Fluid replacement, for toxic epidermal necrolysis, 491 Hair care, adverse reactions to, 690-692 5-Fluorouracil, for photoaging, 105 biology of, 651-658 Flutamide, for androgenetic alopecia, 51 anatomy in, 651-652 Foam boosters, in cosmetics, adverse reactions to, 690 composition in, 652 Folic acid, for androgenetic alopecia, 55 growth cycle in, 652 Follicular infrainfundibulum, androgen metabolism in, hair damage, 655 69 historical aspects of, 651 Folliculitis, eosinophilic, with HIV infection, physical properties in, 653-655 phototherapy for, 517 shape in, 653 unusual remedies for, 327 structure in, 652-653 Folligen, for androgenetic alopecia, 55 cleansers in, 655-656 Food and Drug Administration, and dermatologic formulation of, 655 health care, 315 types of shampoos, 655-656 Forearm controlled application technique, of efficacy, of conditioners in, 656-657 skin cleansers, 572 for photoprotection, 657 Forearm wash test, of efficacy, of skin cleansers, 572 for shine, 656 Formaldehyde-releasing preservatives, in cosmetics, for static electricity, 656-657 adverse reactions to, 688-689 for strength, 657 Formula 101, for androgenetic alopecia, 54 in adolescents. See Cosmetics. Fotemustine, for melanoma, 161 in women of color, 664-665 Foundations, facial. See Colored facial cosmetics. Hair disorders, unusual remedies for, 327-328 Fragrance, in cosmetics, adverse reactions to, 686 Hallopeau's acrodermatitis, treatment of, 341 in hair care products, adverse reactions to, 691 Head lice, treatment of, in children, 77 in skin cleansers, 569-570 Health Care Financing Administration, and Frames! Ravivett, in hair care products, adverse dermatologic health care, 315-316 reactions to, 691 Health Care Utilization Project-n3, in inpatient Full-thickness skin grafts. See Skin grafts. dermatology, 386-389 Fumaric acid esters, for psoriasis, 17-18 Helicobacter pylori, and rosacea, 68-69 Furunculosis, unusual remedies for, 327 Hematologic toxicity, of pulse intravenous cyclophosphamide, 461 Hematoma, periorbital, unusual remedies for, 323-324 Gamma benzene hexachloride, for head lice, in Hemorrhagic cystitis, pulse intravenous children, 77 cyclophosphamide and, 462 Ganciclovir, for infectious diseases, 31-32 Hepatic fibrosis, methotrexate and, 476 Gastrointestinal toxicity, of pulse intravenous Hepatic veno-occlusive disease, thioguanine and, 480 cyclophosphamide, 461 Herbs, cosmetic uses of, in future, 701-702 Gene therapy, 177-188 Herpes gestationis, pulse intravenous clinical perspectives on, 186 cyclophosphamide for, 469 delivery techniques in, 181 Herpes labialis, recurrent, prevention of, lip cosmetics for androgenetic alopecia, 59 in, 648 gene gun approach in, 184-186 Herpes simplex infection, unusual remedies for, 331 gene inhibition in, 181-182 vaccines for, search for, 34 promoter-based gene expression in, 183 Herpes zoster, disseminated, inpatient treatment of, skin as target for, 180-181 506-507 stem cell research in, 183 Hidradenitis suppurativa, unusual remedies for, 331 targeted mutation correction in, 182-183 Highly active anti-retroviral therapy, for HIV infection, GI198745, for androgenetic alopecia, 58 510 Glomerulonephritis, pulse glucocorticoids for, 439 for infectious diseases, 32 Glucocorticoids, pulse. See Pulse glucocorticoids. Histiocytoma, malignant fibrous, clinical features of, Glycerin, in skin cleansers, 568 545-546 Glycolic acid, for melasma, 94 HIV infection, cutaneous drug eruptions with, 511, 513 for postinflammatory hyperpigmentation, 96-97 inpatient treatment of, 509-520 Goa powder, for psoriasis, 430 CD4+ cell count and viral load in, 510 Goeckerman regimen, for psoriasis, 429-430 drug interactions in, 513-515 Gonadal toxicity, of pulse intravenous highly active anti-retroviral therapy in, 510 cyclophosphamide, 461-462 phototherapy in, 515, 517 Gonadotropin-releasing hormone agonists, to prevent for eosinophilic folliculitis, 517 gonadal damage, from pulse intravenous for idiopathic pruritus, 517 cyclophosphamide, 462 for pruritic pustular eruptions, 517 Grafts, skin. See Skin grafts. for psoriasis, 515, 517 Graftskin, as skin substitute, 529 sexual history in, 510 Graft-versus-host disease. See Lichenoid dermatoses. travel history in, 510 Granuloma annulare, unusual remedies for, 330 psoriasis with, 427 Graves' disease, pulse glucocorticoids for, 438 vaccines for, search for, 34 Grenz ray therapy, unusual uses for, 336 Hivid, for HIV infection, drug interactions with, Griseofulvin, for tinea capitis, in children, 73 514-515 HIV-tat inhibitors, for Kaposi's sarcoma, 173-174 Hormonal therapy, for acne, 67-68 Habit tic nail deformity, unusual remedies for, 333 Hormones, and photoaging, 105 734 CUMULATIVE INDEX 2000 Horsetail, for androgenetic alopecia, 57 Ingram regimen, for psoriasis, 431 Human chorionic gonadotropin, for Kaposi's sarcoma, Ingrown toenail, unusual remedies for, 324 173 Inpatient dermatology, 383-390 Hutchinson's sign, in melanonychia striata, 40 consultation in, 533-542 Hydrating agents. See Moisturizers. business aspects of, 540 Hydroquinone, for melasma, 92-94 curbside, 540, 542 for postinflammatory hyperpigmentation, 96 diagnosis and treatment alterations in, 537 Hyperhidrosis, unusual remedies for, 331 equipment and supplies in, 539 Hypericin, for cutaneous T-cell lymphomas, 151 patient characteristics in, 534, 537 Hyperpigmentation, in women of color, cosmetics for, prevalence of skin disease in, 534 661-662 reason for admission in, 533-534 treatment of, 91-98 staffing in, 539 drug-induced disorders, 95 success of, definitions of, 538-539 erythema dyschromicum perstans, 95-96 factors crucial to, 537-538 melasma, 91-95 systemic disorders in, 539-540 azelaic acid in, 94 cutaneous infections in. See Cutaneous infections. chemical peels in, 94 cutaneous T-cell lymphomas in. See Cutaneous T-cell dermabrasion in, 94 lymphomas. glycolic acid in, 94 erythroderma in. See Erythroderma. hydroquinone in, 92-94 graft-versus-host disease in. See Lichenoid dermatoses. kojic acid in, 94 health care delivery systems and, 391-395 laser therapy in, 94-95 materials and methods in, 391-392 tretinoin in, 94 case-mix index, 392 postinflammatory disorders, 96-97 statistics, 392 Hypersensitivity, pulse intravenous cyclophosphamide results of, 392-394 and, 464 analysis of outliers for length of stay, 393-394 case-mix index for different insurance groups, 393 HIV infection in. See HIV infection. lamin, for androgenetic alopecia, 54 immunosuppressants in. See Immunosuppressants. Idiopathic pruritus, with HIV infection, phototherapy in United Kingdom, 399-400 for, 517 in United States, 398 Idiopathic thrombocytopenic purpura, pulse managed care and, 398-399 glucocorticoids for, 438-439 versus United Kingdom, 400-402 IM 862, for Kaposi's sarcoma, 171 intravenous immunoglobulin in. See Intravenous immu¬ Imiquimod, for molluscum contagiosum, in children, noglobulin. 76-77 national perspective on, 385-389 Immunoapheresis, for pemphigus, of oral cavity, Health Care Utilization Project-n3, 386-389 121-122 Medicare Provider Analysis and Review file in, Immunomodulatory agents, for atopic dermatitis, 3-4, 386-389 6-7 plan of action for, 389 for vitiligo, 85-88 psoriasis in. See Psoriasis. Immunosuppressants, clinical uses of, 475-483 pulse glucocorticoids in. See Pulse glucocorticoids. azathioprine, 476-477 pulse intravenous cyclophosphamide in. See Pulse in¬ chlorambucil, 480-481 travenous cyclophosphamide. cyclosporine, 477-478 skin grafts in. ^e Skin grafts. for cutaneous vasculitis, 144 status of, in U.S. academic programs, 383-385 methotrexate, 475-476 toxic epidermal necrolysis in. See Toxic epidermal necro¬ mycophenolate mofetil, 479-480 lysis. tacrolimus, 478-479 Insect bites, unusual remedies for, 332 thioguanine, 480 Integra, as skin substitute, 528 Impetigo, treatment of, in children, 75 Interferons, for aphthous stomatitis, 116 Indomethacin, to prevent photoaging, 101 for atopic dermatitis, 6 Infections, cutaneous. See Cutaneous infections. for cutaneous T-cell lymphomas, 151-154 nontuberculous mycobacterial, of skin. See Nontubercu- for Kaposi's sarcoma, 171 lous mycobacterial skin infections. for lichen planus, 22-23 opportunistic, pulse intravenous cyclophosphamide for melanoma, 161-162 and, 463 Interleukins, for cutaneous T-cell lymphomas, 149-152 Infectious diseases, treatment of, 31-35 for graft-versus-host disease, 25 antibiotics in, 32-33 for Kaposi's sarcoma, 174 antifungal agents in, 32 for melanoma, 161-162 antiviral agents in, 31-32 Intertrigo, crural, unusual remedies for, 331-332 in children, 75-76 Intravenous immunoglobulin, 447-457 ivermectin in, 33 clinical uses of, 451^55 thalidomide in, 33 atopic and allergic dermatoses, 454-455 vaccines in, 33-34 bullous diseases, 453-454 Inflammatory dermatoses, intravenous immunoglobulin dermatomyositis, 451-453 for. See Intravenous immunoglobulin. for atopic dermatitis, 6-7 Inflammatory polyneuropathy, pulse glucocorticoids for, for cutaneous lupus erythematosus, 140 438 for pemphigus, of oral cavity, 122 CUMULATIVE INDEX 2000 735 mucocutaneous drag reactions, 454 Lichen sclerosus et atrophicus, versus localized toxic epidermal necrolysis, 492 scleroderma, 142-143 composition of, 447-449 Lichenoid dermatoses, treatment of, 21-29 mechanism of action of, 449-451 graft-versus-host disease, 24-27, 422-423 acceleration of IgG catabolism, 450-451 CAMPATH-1 monoclonal antibodies in, 25 alteration of inflammatory cytokine production, 450 clinical features of, 417-418 anti-idiotype interactions, 449 cytokine antagonists in, 25 effects on complement, 450 pathogenesis of, 418 Fc receptor interactions, 449-450 photopheresis in, 420-422 neutralization of toxins and superantigens, 450 psoralen UV light in, 25 lodopropynyl butylcarbamate, in cosmetics, adverse tacrolimus in, 16 reactions to, 689-690 lichen nitidus, 23-24 Isolated limb perfusion, for melanoma, 159-160 lichen planus, 21-23 Isotretinoin, for acne. See Acne. cyclosporine in, 21-22 for cutaneous lupus erythematosus, 141 enoxaparin in, 23 for rosacea, 68 interferons in, 22-23 Itraconazole, for HIV infection, drag interactions with, levamisole in, 22 513 of nails, 342 for infectious diseases, 32 of oral cavity. See Oral cavity diseases. for onychomycosis, 41-42 photophoresis in, 23 in children, 44 psoralens and UV light in, 22 for tinea capitis, in children, 74-75 retinoids in, 22 Ivermectin, for head lice, in children, 77 thalidomide in, 23 for infectious diseases, 33 toxic epidermal necrolysis, 24 for scabies, in children, 77 Linear immunoglobulin A bullous dermatosis, treatment of, 132 Lip cosmetics, 641-649 adverse effects of, 645-647 Juglone, as tanning agent, 595 allergic reactions, 646-647 cheilitis, 646 micropigmentation, 645-646 balms, 644 Kaposi's sarcoma, treatment of, 169-175 historical aspects of, 558-559, 641 antiangiogenic factors in, 171-172 in beautification, 648 chemotherapy in, 169-171 lipsticks, 642-644 cytotoxic agents in, 169-171 protective effects of, 647-648 HIV-tat inhibitors in, 173-174 sunscreens in, 644-645 human chorionic gonadotropin in, 173 tattooing in, 645 interferons in, 171 therapeutic, 645 interleukins in, 174 Lipids, epidermal, in moisturizers, 597 retinoic acids in, 172-173 Lupus erythematosus, cutaneous, treatment of. See Kathon CG, in cosmetics, adverse reactions to, 689 Collagen-vascular diseases. Keratoacanthoma, unusual remedies for, 325 Lyell's syndrome, treatment of, 24 Ketoconazole, for HIV infection, drag interactions with, Lyme disease, vaccines for, 33-34 513 Lymph node biopsies, sentinel, for melanoma, 158-159 Kevis Hair Rejuvenation Program, for androgenetic Lymph node dissection, elective, for melanoma, 157-158 alopecia, 53-54 Lymphatic mapping, for melanoma, 158 Kojic acid, for melasma, 94 Lymphomas, cutaneous T-cell. See Cutaneous T-cell lymphomas. Lanolin, in cosmetics, adverse reactions to, 692 Laser resurfacing, for photoaging, 106-109 Maidenhair, for androgenetic alopecia, 57 Laser therapy, for androgenetic alopecia, 60 Malignancies, cyclosporine and, 478 for melasma, 94-95 pulse intravenous cyclophosphamide and, 465, 466 Lawsone, as tanning agent, 595 Malignant fibrous histiocytoma, clinical features of, Leg ulcers, chronic, split-thickness skin grafts for, 545-546 523-524 Manicure products, dermatologic aspects of, 675-678 unusual remedies for, 335 Mascara, dermatologic aspects of, 637-638 Leg wash test, of efficacy, of skin cleansers, 572-573 Medicare Provider Analysis and Review file, in Leiomyosarcoma, clinical features of, 549-550 inpatient dermatology, 386-389 Leprosy, in developing world, 208 Medicated shampoos, in hair care, 656 Leukemia, chlorambucil and, 481 MEDLINE, in evidence-based dermatologic health care, Leukotrit'ne inhibitors, for atopic dermatitis, 8 263-264 Levamisole, for aphthous stomatitis, 115 Melanin, as tanning agent, 595 for lichen planus, 22 Melanocytes, repopulation of, for vitiligo, 80-81 for vitiligo, 87 transplantation of, for vitiligo, 83-85 Lice, treatment of, in children, 77 Melanoma, subungual, versus melanonychia striata, Lichen nitidus, treatment of, 23-24 39-41 Lichen planus. See Lichenoid dermatoses. treatment of, 157-167 736 CUMULATIVE INDEX 2000 Melanoma (Continued) Mucous membrane pemphigoid, treatment of, 117-118, biochemotherapy in, 161-162 129-131 chemotherapy in, 161 Multiple sclerosis, pulse glucocorticoids for, 438, 442 elective lymph node dissection in, 157-158 Mupirocin, for infectious diseases, 32-33 lymphatic mapping and sentinel lymph node biops¬ Mycobacterial infections, nontuberculous, of skin. See ies in, 158-159 Nontuberculous mycobacterial skin infections. radiation therapy in, 163-164 Mycophenolate mofetil, clinical uses of, 479-480 surgical, 159-160 for atopic dermatitis, 7 vaccines in, 162-163 for bullous pemphigoid, 129 Melanonychia striata, treatment of, 39-41 for pemphigoid, of oral cavity, 117 Melasma, treatment of. See Hyperpigmentation. for pemphigus, 133 Meningococcemia, inpatient treatment of, 504-506 of oral cavity, 120 Menthyl anthranilate, in sunscreens, 583 for psoriasis, 17 Merkel's cell carcinoma, clinical features of, 548-549 Mycosis fungoides, treatment of. See Cutaneous T-cell Meshed grafts, in split-thickness skin grafts, 525 lymphomas. Mesna, with pulse intravenous cyclophosphamide, 462 Methotrexate, clinical uses of, 475-476 for atopic dermatitis, 4, 6 for bullous pemphigoid, 128-129 Nail cosmetics, 675-683 for cutaneous dermatomyositis, 141 adornments, 678 for cutaneous vasculitis, 144 adverse reactions to, 692 for localized scleroderma, 142 artificial sculptures, 680-683 for psoriasis, 355-356 artificial tips, 678, 680 unusual uses of, 336 historical aspects of, 559 Metronidazole, for rosacea, 68 manicure products, 675-676 Mexoryl SX, in sunscreens, 583 French, 677-678 Micanol, for psoriasis, 13 polish, 676-677 Microdermabrasion, for photoaging, 108 Nail disorders, anatomy and physiology of, 340 Micropigmentation, for vitiligo, 83 treatment of, 339-348 lip cosmetics and, 645-646 brittle nails, 344 Minocycline, and hyperpigmentation, 95 eczema, 344 for acne, 65-66 Hallopeau's acrodermatitis, 341 Minority populations, dermatologic health care in, lichen planus, 342 229-233 onycholysis, 345 future directions in, 231-232 onychomycosis, 346-347 patient-related barriers to, 229-230 onychotillomania, 346 provider-related barriers to, 230-231 parakeratosis pustulosa, 343 Minoxidil, for androgenetic alopecia, 49 paronychia, 344-345 in women, 58-59 psoriasis, 340-341 Mohs' micrographic surgery, for dermatofibrosarcoma twenty-nail dystrophy, 343-344 protuberans, 544 yellow nail syndrome, 345-346 for malignant fibrous histiocytoma, 546 unusual remedies for, 324, 332-333 for skin cancer, 257 Moisturizers, 597-607 National Ambulatory Medical Care Survey, 223-227 alpha hydroxy acids in, 601-602 methods used in, 223-224 and physiology of xerosis, 597-598 results of, 224-226 beta hydroxy acid in, 602-603 complexity of care, 225-226 combination hydroxy acids in, 603 comprehensive care, 224-225 efficacy of, 606 continuity of care, 224 emolliency of, 599-601 coordination of care, 225 epidermal lipids in, 597 Necrotizing fasciitis, inpatient treatment of, 498-499 in adolescents, 669 Neuroleptic malignant syndrome, antipsychotic agents in epidermal barrier repair, 598 and, 721 mechanism of action of, 598-599 Nevirapine, for HIV infection, adverse effects of, 513 humectant, 599 Nicotinamide, in moisturizers, 605-606 occlusive, 598-599 Nioxin System, for androgenetic alopecia, 55-56 niacinamide in, 605-606 Nitrosoureas, for melanoma, 161 panthenol in, 605 Nizoral, for HIV infection, drug interactions with, 513 polyhydroxy acids in, 603 Nonchromogens, in nontuberculous mycobacterial skin sodium PCA in, 601 infections, 365-370 urea in, 601 Nonsteroidal anti-inflammatory drugs, and toxic vitamins, 603-605 epidermal necrolysis, 487 Molluscum contagiosum, treatment of, in children, Nontuberculous mycobacterial skin infections, 359-377 76-77 classification of, 359 unusual remedies for, 325 Mycobacterium abscessus in, 372, 374 Moniliasis, unusual remedies for, 332 Mycobacterium avium complex in, 365-366, 369 Monoclonal antibodies, for graft-versus-host disease, 25 Mycobacterium chelonei in, 371-372 Montelukast, for atopic dermatitis, 8 Mycobacterium fortuitum in, 370-371 Morphea, unusual remedies for, 332 Mycobacterium haemophilum in, 369, 370 Mucocutaneous drug reactions, intravenous Mycobacterium kansasii in, 363-364 immunoglobulin for, 454 Mycobacterium marinum in, 360-362